Quarterly Result15 Jan 2026, 05:51 pm
Genomic Valley Biotech Ltd. Reports Q3 and Nine Months Financial Results for 2025, Announces Director's Resignation
AI Summary
Genomic Valley Biotech Ltd. has reported its financial results for the quarter and nine months ended 31 December 2025. The company's revenue from operations stands at 5,00,000 for the current quarter, a significant increase from the previous year. The total revenue for the current period is 58,80,795. The company's total expenses amount to 15,75,499, resulting in a comprehensive income of 3,84,786. The Board of Directors also accepted the resignation of Mr. Ashok Kumar from his directorship. The meeting was held on 15 January 2026.
Key Highlights
- Genomic Valley Biotech Ltd. reports Q3 and nine months financial results for 2025.
- Revenue from operations stands at 5,00,000 for the current quarter.
- Total revenue for the current period is 58,80,795.
- Total expenses amount to 15,75,499, resulting in a comprehensive income of 3,84,786.
- Mr. Ashok Kumar ceases to be a Director and a Member of all Committees of the Company.
Price Impact
More from GVBL